Aptose Biosciences Inc. (APTO) Upgraded to “Hold” by Zacks Investment Research
Aptose Biosciences Inc. (NASDAQ:APTO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
A number of other equities analysts also recently issued reports on the stock. RBC Capital Markets reissued an “outperform” rating on shares of Aptose Biosciences in a research note on Tuesday, September 13th. Royal Bank Of Canada reissued an “outperform” rating and issued a $23.00 price target on shares of Aptose Biosciences in a research note on Saturday, June 25th. Finally, Roth Capital upgraded shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $4.00 to $8.00 in a report on Monday, June 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Aptose Biosciences has a consensus rating of “Buy” and a consensus target price of $12.30.
Shares of Aptose Biosciences (NASDAQ:APTO) traded up 5.2168% on Tuesday, hitting $2.3779. The stock had a trading volume of 29,362 shares. The company’s market capitalization is $30.66 million. The firm has a 50-day moving average of $2.18 and a 200 day moving average of $2.47. Aptose Biosciences has a 1-year low of $1.92 and a 1-year high of $6.40.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent filing with the SEC. The fund purchased 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned 0.43% of Aptose Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 19.47% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.